Список литературы

1. Van Wyck D.B. et al. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease (2012) [Electronic resource]. 2012. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney inter., Suppl. 2012; 2

2. National Collaborating Centre for Chronic Conditions (UK). Anaemia Management in Chronic Kidney Disease: National Clinical Guideline for Management in Adults and Children [Electronic resource]. 2006. URL: https://pubmed.ncbi.nlm.nih.gov/20945579/ (accessed: 20.07.2020).

3. McMurray J.J. V. et al. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease//Kidney Int. Suppl. 2012. Vol. 2, N 4. P. 279 - 331.

4. Мак-Дугалл И., пер. с англ под ред. Котенко О.Н. Карманный справочник по нефрогенной анемии. М.: ГЭОТАР-Медиа, 2015

5. Kimachi M. et al. Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients//Nephron 2015.131: 123 - 130 Doi: 10.1159/000438870

6. Шило В.Ю., Земченков А.Ю., Гуревич К.Я., Добронравов В.А., Лысенко (Козловская) Л.В., Ермоленко В.М., Смирнов А.В., Томилина Н.А., Хасабов Н.Н., Шилов Е.М., Шостка Г.Д. Российские национальные рекомендации по диагностике и лечению анемии при хронической болезни почек. Нефрология и диализ. 2016; 18(1): 19 - 34.

7. Koulouridis I., et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013. 61(1): 44 - 56.

8. Павлов А.Д., Морщакова Е.Ф., Румянцев А.Г. Эритропоэз, эритропоэтин, железо. М.: ГЭОТАР-Медиа, 2011. 304 p.

9. Van Wyck D.B. et al. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target [Electronic resource]. 2007.

10. Менделеева Л.П., Вотякова О.М., Рехтина И.Г. Множественная миелома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний./ed. Поддубной И.В., Савченко В.Г. Москва, 2018. 213 - 241 p.

11. Rajkumar S.V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma//The Lancet Oncology. Lancet Publishing Group, 2014. Vol. 15, N 12. P. e538 - e548.

12. Misra A. et al. Old but Still Relevant: High Resolution Electrophoresis and Immunofixation in Multiple Myeloma//Indian Journal of Hematology and Blood Transfusion. Springer India, 2016. Vol. 32, N 1. P. 10 - 17.

13. Julie D. et al. Comparison of Bone marrow Aspirate and Bone marrow Biopsy in the workup of Patients with Multiple Myeloma//Clin. Lymphoma Myeloma Leuk. Elsevier BV, 2015. Vol. 15. P. e117.

14. Hill Q, Stamps R, Massey E et al. The diagnosis and management of primary autoimmune haemolitic anamia Br J Haematol 2017; 176: 395 - 411.

15. Shutov E et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not ondialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol DialTransplant. 2021. Epub 2021/02/26. pmid: 33630072

16. Yap, DYH et al. Recommendations by the Asian Pacific society of nephrology (APSN) on theappropriate use of HIF-PH inhibitors. Nephrology. 2021; 26: 105 - 118. p. 108. https://doi.org/10.1111/nep.13835

17. Lei J., Li H., and Wang S. Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients//Hindawi BioMed Research International Volume 2022, Article ID 2413176, 12 pages https://doi.org/10.1155/2022/2413176

18. Шутов Е.В. Горелова Е.А., Сороколлетов С.М. Ингибиторы пролилгидроксилазы индуцируемого гипоксией фактора в лечении анемии больных с хронической болезнью почек. Эффективная фармакотерапия 2022. Том 18; N 3. Урология и нефрология Стр. 22 - 30.

19. Chonchol M. et al. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis//Nephrology Dialysis Transplantation. - 2008. - Т. 23. - N. 9. - С. 2879 - 2883.

20. Nand N. et al. Role of high-sensitivity C-reactive Protein as a Marker of Inflammation in pre-dialysis patients of chronic renal failure//JIACM. - 2009. - Т. 10. - N. 1. - С. 18 - 22.

21. Mikhail A. et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease//BMC nephrology. - 2017. - Т. 18. - С. 1 - 29.

22. Mikhail A. et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease//BMC nephrology. - 2017. - Т. 18. - С. 1 - 29.

23. Daud W. R. W., Shah S. A., Ali R. A. R. Endoscopic findings among geriatric patients with anaemia and chronic kidney disease at a tertiary teaching hospital in Malaysia//Med J Malaysia. - 2022. - Т. 77. - С. 284 - 291.

24. Agudo R. et al. Gastrointestinal lesions in chronic kidney disease patients with anemia// (English Edition). - 2019. - Т. 39. - N. 1. - С. 50 - 57.

25. Chonchol M. et al. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis//Nephrology Dialysis Transplantation. - 2008. - Т. 23. - N. 9. - С. 2879 - 2883.

26. Nand N. et al. Role of high-sensitivity C-reactive Protein as a Marker of Inflammation in pre-dialysis patients of chronic renal failure//JIACM. - 2009. - Т. 10. - N. 1. - С. 18 - 22.

27. Keshk R. A. et al. Relation between intact parathyroid hormone and hemoglobin level in chronic kidney disease patients on hemodialysis//Tanta Medical Journal. - 2016. - Т. 44. - N. 4. - С. 170 - 175.

28. Russo D. et al. Parathyroid hormone may be an early predictor of low serum hemoglobin concentration in patients with not advanced stages of chronic kidney disease//Journal of Nephrology. - 2015. - Т. 28. - С. 701 - 708.

29. Cannata J. B. et al. Serum aluminum transport and aluminum uptake in chronic renal failure: role of iron and aluminum metabolism//Nephron. - 1993. - Т. 65. - N. 1. - С. 141 - 146.

30. Palmer S. C. et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis//Cochrane Database of Systematic Reviews. - 2014. - N. 12.

31. Bruce G., Schulga P., Reynolds B. C. Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review//Clinical Kidney Journal. - 2022. - Т. 15. - N. 8. - С. 1483 - 1505.

32. Tang M. et al. Safe and effective treatment for anemic patients with chronic kidney disease: an updated systematic review and meta-analysis on roxadustat//Frontiers in pharmacology. - 2021. - Т. 12. - С. 658079.

33. Qie S. et al. The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review//International urology and nephrology. - 2021. - Т. 53. - С. 985 - 997.

34. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Vol. 105, Issue 4, Suppl. S117 - S314.

35. Koshy S.M., Geary D.F. Anemia in children with chronic kidney disease//Pediatr. Nephrol. 2008. Vol. 23. P. 209 - 219.

36. Kaufman J.S., Reda D.J., Fye C.L. et al. Subcutaneous compared with in travenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients//N. Engl. J. Med. 1998. Vol. 339. P. 578 - 583.

37. Пропедевтика внутренних болезней: учебник/Н.А. Мухин, В.С. Моисеев. - 2-е изд., доп. и перераб. - М.: ГЭОТАР-Медиа, 2020. Стр. 519 - 521